A conserved dendritic-cell regulatory program limits antitumour immunity

B Maier, AM Leader, ST Chen, N Tung, C Chang… - Nature, 2020 - nature.com
Checkpoint blockade therapies have improved cancer treatment, but such immunotherapy
regimens fail in a large subset of patients. Conventional type 1 dendritic cells (DC1s) control …
被引用次数：659 相关文章

A conserved dendritic-cell regulatory program limits antitumour immunity.

B Maier, AM Leader, ST Chen, N Tung, C Chang… - Nature, 2020 - go.gale.com
Checkpoint blockade therapies have improved cancer treatment, but such immunotherapy
regimens fail in a large subset of patients. Conventional type 1 dendritic cells (DC1s) control …

A conserved dendritic-cell regulatory program limits antitumour immunity

B Maier, AM Leader, ST Chen, N Tung, C Chang… - Nature, 2020 - econpapers.repec.org
Checkpoint blockade therapies have improved cancer treatment, but such immunotherapy
regimens fail in a large subset of patients. Conventional type 1 dendritic cells (DC1s) control …

A conserved dendritic-cell regulatory program limits antitumour immunity

B Maier, AM Leader, ST Chen, N Tung, C Chang… - Nature, 2020 - ideas.repec.org
Checkpoint blockade therapies have improved cancer treatment, but such immunotherapy
regimens fail in a large subset of patients. Conventional type 1 dendritic cells (DC1s) control …

A conserved dendritic-cell regulatory program limits antitumour immunity.

B Maier, AM Leader, ST Chen, N Tung, C Chang… - Nature, 2020 - europepmc.org
Checkpoint blockade therapies have improved cancer treatment, but such immunotherapy
regimens fail in a large subset of patients. Conventional type 1 dendritic cells (DC1s) control …
[HTML] nih.gov

[HTML][HTML] A conserved dendritic-cell regulatory program limits antitumour immunity

B Maier, AM Leader, ST Chen, N Tung, C Chang… - Nature, 2020 - ncbi.nlm.nih.gov
Checkpoint blockade therapies have improved cancer treatment, but such immunotherapy
regimens fail in a large subset of patients. Conventional type 1 dendritic cells (DC1s) control …

A conserved dendritic-cell regulatory program limits antitumour immunity

B Maier, AM Leader, ST Chen, N Tung, C Chang… - …, 2020 - pubmed.ncbi.nlm.nih.gov
Checkpoint blockade therapies have improved cancer treatment, but such immunotherapy
regimens fail in a large subset of patients. Conventional type 1 dendritic cells (DC1s) control …

A conserved dendritic-cell regulatory program limits antitumour immunity

B Maier, AM Leader, ST Chen, N Tung, C Chang… - …, 2020 - ui.adsabs.harvard.edu
Checkpoint blockade therapies have improved cancer treatment, but such immunotherapy
regimens fail in a large subset of patients. Conventional type 1 dendritic cells (DC1s) control …

A conserved dendritic-cell regulatory program limits antitumour immunity

B Maier, AM Leader, ST Chen, N Tung, C Chang… - paper.sciencenet.cn
Checkpoint blockade therapies have improved cancer treatment, but such immunotherapy
regimens fail in a large subset of patients. Conventional type 1 dendritic cells (DC1s) control …

[引用][C] A conserved dendritic-cell regulatory program limits antitumour immunity

B Maier, AM Leader, ST Chen, N Tung, C Chang… - Nature, 2020 - cir.nii.ac.jp